Teva Pharmaceutical Industries Limited
NYSETeva Pharmaceutical Industries reported Q2 results on July 29, and with the stock recovering to $31.67 — up 1.9% on the day and roughly 1% on the week — the immediate market reaction has been mildly constructive, even as the shares remain about 4% below where they traded a month ago. The most notable development this week came from Piper Sandler's David Amsellem, who raised his…
TEVA short interest surges 23.3% over one week to 33.8M shares, with vast availability cushioning short-seller demand at 1,899% of SI.
Snapshot as of 6 Aug 2026
Teva Pharmaceutical Industries reported Q2 results on July 29, and with the stock recovering to $31.67 — up 1.9% on the day and roughly 1% on the week — the immediate market reaction has been mildly constructive, even…
TEVA enters its July 29 second-quarter earnings report having shed 7% over the past month to $30.81, with the stock down another 4% on the week. That recent softness stands in contrast to the analyst consensus, and the…
Teva Pharmaceutical Industries enters the week with a rare burst of momentum. A strong Q1 earnings print sent the stock up nearly 11% on April 29 alone. The stock is now up 13% on the week and 19% over the past month,…
TEVA heads into its May 6 Q1 results on the back of a rare wave of unanimous bullishness from the Street, with the stock already up 14% on the week and 16% over the past month to $34.95. The analyst signal here is…
TEVA reports Wednesday morning with its short positioning at a three-month low and options traders showing little conviction either way. Short interest fell 14% over the past month to 26.7 million shares. Cost to…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TEVA — free to start on ORTEX.
Sign up for free →Open TEVA on ORTEX